CriticalSecond-generation systemic triazole antifungal×Antitubercular, rifamycin derivative
Updated · Methodology
Mechanism
Rifabutin induces the enzyme CYP3A4, and its main metabolite strengthens this effect (rifabutin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP3A4 and CYP3A5 metabolise isavuconazole (isavuconazole SmPC, European Medicines Agency, EMA). The European isavuconazole SmPC lists rifabutin among strong CYP3A4/5 inducers that may markedly lower isavuconazole levels, although the two drugs have not been studied together (EMA). According to the rifabutin SmPC, rifabutin is a 2–3 times weaker inducer than rifampicin (AEMPS). In the other direction, isavuconazole moderately inhibits CYP3A4 (isavuconazole SmPC and label, EMA and US Food and Drug Administration, FDA). CYP3A4 inhibitors may raise rifabutin levels (rifabutin SmPC and label, AEMPS and FDA): fluconazole increased rifabutin exposure (area under the curve, AUC) by 82% and posaconazole by 72% (AEMPS). There are no measurements with isavuconazole.
Symptoms
Rifabutin may markedly lower isavuconazole levels (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). The size of the effect has not been measured for this pair. If isavuconazole raises rifabutin levels, rifabutin adverse reactions may increase, including uveitis, inflammation of the middle layer of the eye, from mild to severe (rifabutin SmPC and label, Spanish Agency of Medicines and Medical Devices, AEMPS, and US Food and Drug Administration, FDA). When rifabutin is combined with fluconazole and other antifungals of the same class, the rifabutin documents call for close monitoring for uveitis (AEMPS, FDA).
Management
The combination is contraindicated: the European isavuconazole SmPC names rifabutin explicitly among strong CYP3A4/5 inducers that must not be given with isavuconazole (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). The US isavuconazole label contraindicates strong CYP3A4 inducers, giving rifampicin, carbamazepine, St John's wort and long-acting barbiturates as examples. It does not name rifabutin (isavuconazole label, US Food and Drug Administration, FDA). The rifabutin documents do not name isavuconazole. With azole antifungals, they state that the rifabutin dose may need to be reduced. With fluconazole and related drugs, they require monitoring for uveitis (rifabutin SmPC and label, Spanish Agency of Medicines and Medical Devices, AEMPS, and FDA). If uveitis develops, refer the patient to an ophthalmologist and stop rifabutin if necessary (AEMPS). No document gives a waiting time between stopping rifabutin and starting isavuconazole. The half-life of rifabutin is about 35–40 hours (AEMPS), and the mean half-life of isavuconazole is 130 hours (FDA). During long-term rifabutin treatment, check the full blood count and liver enzymes periodically (AEMPS). With isavuconazole, evaluate liver tests at the start and during treatment (FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Rifabutina (nº registro 60228), sección 4.5 (2026)– AEMPS, CIMA, nº registro 60228, revisión 04/2026, secciones 4.4 y 4.5
- FDA: Rifabutin capsules USP, Mylan (rifabutin) prescribing information (2026)– FDA, DailyMed setid c2026b67-4755-4236-96b6-a6b5e7399707, revisión 07/2026 (versión 14), Warnings (Uveitis) y Precautions, Drug Interactions, tabla 2
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.5 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4, 4.5, 4.9 y 5.2
- FDA: CRESEMBA (isavuconazonium sulfate) prescribing information (2025)– FDA, DailyMed setid 8f7f73b8-586a-4df0-935f-fecd4696c16c (Astellas Pharma US), revisión 04/2025 (versión 21), secciones 4, 5.1, 5.5, 7, 10 y 12.3
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.3 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5